News headlines about Progenics Pharmaceuticals (NASDAQ:PGNX) have trended somewhat positive on Friday, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Progenics Pharmaceuticals earned a news impact score of 0.05 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.2437794667876 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news articles that may have impacted Accern’s scoring:
- Progenics Pharmaceuticals (PGNX) PT Set at $15.00 by Cantor Fitzgerald (americanbankingnews.com)
- Progenics Talks Commercialization, Pipeline, And Milestones (seekingalpha.com)
- Progenics Pharmaceuticals’ (PGNX) Buy Rating Reaffirmed at Aegis (americanbankingnews.com)
- Progenics Pharmaceuticals (PGNX) Downgraded by Zacks Investment Research to “Sell” (americanbankingnews.com)
- Equities Analysts Set Expectations for Progenics Pharmaceuticals, Inc.’s FY2018 Earnings (PGNX) (americanbankingnews.com)
PGNX stock opened at $7.34 on Friday. The company has a quick ratio of 6.31, a current ratio of 6.31 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $525.35, a P/E ratio of -8.16 and a beta of 2.46. Progenics Pharmaceuticals has a 1-year low of $4.60 and a 1-year high of $8.63.
Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.21) earnings per share for the quarter, meeting the consensus estimate of ($0.21). The firm had revenue of $3.90 million during the quarter, compared to the consensus estimate of $3.18 million. Progenics Pharmaceuticals had a negative return on equity of 87.30% and a negative net margin of 436.08%. The firm’s quarterly revenue was down 15.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.10) earnings per share. sell-side analysts anticipate that Progenics Pharmaceuticals will post -0.8 EPS for the current fiscal year.
Several research firms recently weighed in on PGNX. Zacks Investment Research downgraded Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, April 7th. Cantor Fitzgerald set a $15.00 price objective on Progenics Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, March 22nd. BidaskClub upgraded Progenics Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 8th. Finally, ValuEngine downgraded Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 16th. Two analysts have rated the stock with a sell rating, three have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $12.35.
TRADEMARK VIOLATION WARNING: “Progenics Pharmaceuticals (PGNX) Given News Sentiment Score of 0.05” was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://ledgergazette.com/2018/04/13/progenics-pharmaceuticals-pgnx-given-news-sentiment-score-of-0-05.html.
About Progenics Pharmaceuticals
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.